Is There Room for Non-Dopaminergic Treatment in Parkinson Disease?
Department
neurology
Document Type
Article
Abstract
Although levodopa and dopaminergic drugs remain the mainstay of therapy for the motor symptoms of Parkinson disease (PD), they fail to address many of the non-motor symptoms of PD including orthostatic hypotension, freezing of gait (FOG) and difficulty with balance, drug-induced paranoia and hallucinations, and drug-induced dyskinesias. Droxidopa, a drug that increases norepinephrine, treats orthostatic hypotension, cholinomimetic drugs sometimes help with FOG and difficulty with balance, pimavanserin, a drug that blocks serotonin receptors, treats paranoia and hallucinations, and anti-glutaminergic drugs treat dyskinesias. Thus, there are ample opportunities for non-dopaminergic drugs in PD.
Medical Subject Headings
neurology
Publication Date
2013
Publication Title
Journal of Neural Transmission
ISSN
0300-9564
Volume
120
Issue
2
First Page
347
Last Page
348
Digital Object Identifier (DOI)
10.1007/s00702-012-0946-0
Recommended Citation
Lieberman, Abraham N. and Krishnamurthi, Narayanan, "Is There Room for Non-Dopaminergic Treatment in Parkinson Disease?" (2013). Neurology. 121.
https://scholar.barrowneuro.org/neurology/121